Browse by author
Lookup NU author(s): Dr Adrien Tissot, Dr Matthew Thomas, Emeritus Professor Nick Europe-Finner, Dr Malcolm Brodlie
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2018 The Author(s). Background: In people with cystic fibrosis infection with NonTuberculous Mycobacteria is of increasing prevalence. Mycobacterium abscessus complex is of particular concern and has been associated with adverse clinical outcomes. Optimal treatment usually requires multiple antibiotics for over 12 months. When considering lung transplantation for patients with NonTuberculous Mycobacteria potential benefits must be balanced against the risks of uncontrolled infection post-transplant and significant side-effects associated with treatment. In this survey we assessed current international practice with regard to assessing and listing patients for lung transplantation. Methods: We designed a questionnaire enquiring about local practice regarding screening for NonTuberculous Mycobacteria infection, specific contra-indications to transplantation, management and segregation of patients pre- and post-transplant. The survey was sent via e-mail to 37 paediatric and adult lung transplant centres across Europe, North America and Australia. Results: We gathered complete questionnaires from 21 centres (57% response rate). Few centres (29%) have a clear written policy regarding NonTuberculous Mycobacteria. Sixteen (76%) centres require molecular identification of NonTuberculous Mycobacteria species. Only four centres would consider infection with M. abscessus complex in itself a contra-indication for listing, however 76% regard it as a relative contra-indication. Eighty-six percent require treatment pre-transplantation. Finally, only 61% of centres had a clear policy regarding segration of patients pre-transplant and 48% post-transplant. Conclusions: The issue of NonTuberculous Mycobacteria infection in people with cystic fibrosis requiring lung transplantation is well-recognized however current international recommendations are not detailed and there is variation in practice between centres. There is an urgent requirement for high quality clinical data to inform decision-making.
Author(s): Tissot A, Thomas MF, Corris PA, Brodlie M
Publication type: Article
Publication status: Published
Journal: BMC Pulmonary Medicine
Year: 2018
Volume: 18
Online publication date: 22/05/2018
Acceptance date: 25/04/2018
Date deposited: 04/06/2018
ISSN (electronic): 1471-2466
Publisher: BioMed Central Ltd
URL: https://doi.org/10.1186/s12890-018-0635-3
DOI: 10.1186/s12890-018-0635-3
Altmetrics provided by Altmetric
